Strides Pharma Science Announces Financial Results and Dividend Recommendation for Fiscal Year Ended March 31, 2026
Bangalore, May 18, 2026 – Strides Pharma Science Limited announced the outcomes of its Board Meeting held on May 18, 2026. The Board approved the audited financial results (standalone and consolidated) for the quarter and the financial year ended March 31, 2026, alongside recommending a final dividend.The Board recommended a final dividend of Rs. 5/- per equity share of Rs. 10/- each, at the rate of 50%, for the financial year ended March 31, 2026.
Financial Performance Highlights
The company released its financial performance data, detailing the results for the quarter and full year ended March 31, 2026, in both consolidated and standalone formats.Consolidated Financial Results
The consolidated results presented the following key figures in Rs. Million:| Particulars | 3 Months ended March 31, 2026 | Current year ended March 31, 2026 | Previous year ended March 31, 2025 |
|---|---|---|---|
| Total Revenue | 13,315.98 | 50,093.96 | 46,240.57 |
| Total Income | 13,315.98 | 50,093.96 | 46,240.57 |
| Total Expenses | 11,785.91 | 43,143.36 | 42,036.34 |
| Profit before tax | 1,480.51 | 6,686.86 | 4,869.21 |
| Profit after tax from continuing operations | 1,292.81 | 5,745.20 | 4,094.05 |
Standalone Financial Results
In the standalone segment, the total income amounted to Rs. 6,097.05 million for the quarter ending March 31, 2026, and Rs. 23,031.98 million for the full year ended March 31, 2026.The standalone profit after tax from continuing operations stood at Rs. 1,836.35 million for the quarter and Rs. 1,836.35 million for the full year ended March 31, 2026.
Consolidated Balance Sheet
The consolidated balance sheet showed an increase in Total Assets, reaching Rs. 69,272.32 million as of March 31, 2026, compared to Rs. 60,487.25 million on the same date in the previous year.| Asset Category | As of March 31, 2026 (AUDITED) | As of March 31, 2025 (AUDITED) |
|---|---|---|
| Total non-current assets | 33,138.93 | 29,498.14 |
| Total current assets | 36,127.93 | 30,989.11 |
| Total Assets | 69,272.32 | 60,487.25 |
The Total Equity and Liabilities also increased, with Total Equity standing at Rs. 31,493.4 million compared to Rs. 25,864.6 million in the prior year.
Cash Flow Analysis
The Statement of Consolidated Cash Flow demonstrated robust operating activity. Cash generated from operating activities reached Rs. 2,778.45 million for the current year, compared to Rs. 4,214.83 million in the previous year. The net cash flow generated from operating activities for the year ended March 31, 2026, was Rs. 2,778.45 million.Segment Reporting
According to the "management approach," the company has only one reportable segment: the Pharmaceutical segment.The Pharmaceutical segment's Total Revenue was Rs. 13,315.98 million for the quarter ended March 31, 2026, and Rs. 50,093.96 million for the full year, while the Profit after tax from continuing operations for the year stood at Rs. 5,745.20 million.
The comprehensive results for the quarter ending December 31, 2025, recorded a gain on disposal of assets/settlement of liabilities attributable to discontinued operations (net) of Rs. 31,881.07 million, as detailed in the financial results.
STAR Stock Price Movement
As of 3:27 PM, shares of Strides Pharma Science Limited are shedding 2.27% in live trading, currently testing ₹1127.5. The notable decline is occurring on substantial interest, with 956,694 shares traded today as the stock moves through the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.